Efficacy and safety of oral recombinant calcitonin tablets in postmenopausal women with low bone mass and increased fracture risk: a randomized, placebo-controlled trial

Osteoporosis International

Volumn 25, Issue 11, 2014, Pages 2649-2656

  Binkley, N ^a   Bone, H ^b   Gilligan, J P ^c   Krause, D S ^c  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b Michigan Bone and Mineral Clinic   (United States)

^c Tarsa Therapeutics Inc   (United States)

Author keywords

Bone mineral density; Calcitonin; Oral; Osteopenia; Osteoporosis

Indexed keywords

PLACEBO; SALCATONIN; BIOLOGICAL MARKER; BONE DENSITY CONSERVATION AGENT; CALCITONIN; COLLAGEN TYPE 1; COLLAGEN TYPE I TRIMERIC CROSS-LINKED PEPTIDE; PEPTIDE;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ACUTE HEPATITIS; AGED; ARTHRALGIA; ARTICLE; BONE DENSITY; BONE MASS; BREAST CANCER; CALCITONIN BLOOD LEVEL; COMPARATIVE STUDY; CONSTIPATION; CONTROLLED STUDY; CONTUSION; DECREASED APPETITE; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DUAL ENERGY X RAY ABSORPTIOMETRY; FAINTNESS; FEMALE; FEMUR NECK; FEVER; FOLLOW UP; FRACTURE; HIP FRACTURE; HUMAN; INJURY; LACERATION; LICHEN PLANUS; LIMB PAIN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MENINGIOMA; NAUSEA; OBESITY; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; PHASE 2 CLINICAL TRIAL; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; RISK FACTOR; SEPSIS; SPINE FRACTURE; TABLET; TIBIA FRACTURE; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; XEROSTOMIA; BLOOD; CLINICAL TRIAL; COMPLICATION; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; HIP; LUMBAR VERTEBRA; MIDDLE AGED; ORAL DRUG ADMINISTRATION; OSTEOPOROSIS, POSTMENOPAUSAL; OSTEOPOROTIC FRACTURES; PATHOPHYSIOLOGY; PHOTON ABSORPTIOMETRY; PROCEDURES; SINGLE BLIND PROCEDURE; TREATMENT OUTCOME;

ABSORPTIOMETRY, PHOTON; ADMINISTRATION, ORAL; AGED; BIOLOGICAL MARKERS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CALCITONIN; COLLAGEN TYPE I; DOUBLE-BLIND METHOD; FEMALE; FEMUR NECK; HIP JOINT; HUMANS; LUMBAR VERTEBRAE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; OSTEOPOROTIC FRACTURES; PEPTIDES; SINGLE-BLIND METHOD; TREATMENT OUTCOME;

EID: 84919873815     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-014-2796-0     Document Type: Article

References (22)

1. Rosen CJ (2001) Treatment of postmenopausal osteoporosis: an evidence-based approach. Rev Endocr Metab Disord 2:35–43
2. Rosen CJ (2005) Clinical practice. Postmenopausal osteoporosis. N Engl J Med 353:595–603
3. Siris ES, Miller PD, Barrett-Connor E et al (2001) Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment. JAMA 286:2815–2822
4. Kanis JA (2010) Development and use of FRAX in osteoporosis. Osteoporos Int 21(Suppl2):S407–S413
5. Siris ES, Boonen S, Mitchell PJ et al (2012) What’s in a name? What constitutes the clinical diagnosis of osteoporosis? Osteoporos Int 23:2093–2097
6. Siris ES, Adler R, Bilezikian J et al (2014) The clinical diagnosis of osteoporosis: a position statement from the National Bone Health Alliance Working Group. Osteoporos Int 25:1439–1443
7. Wysowski DK, Greene P (2013) Trends in osteoporosis treatment with oral and intravenous bisphosphonates in the United States, 2002-2012. Bone 57:423–428
8. Solomon DH, Johnston SS, Boytsov NN, et al (2014) Osteoporosis medication use after hip fracture in U.S. patients between 2002 and 2011. J Bone Miner Res Feb 18 (epub)
9. Chesnut CH 3rd, Azria M, Silverman S et al (2008) Salmon calcitonin: a review of current and future therapeutic indications. Osteoporos Int 19:479–491
10. Kittur SD, Hoppener JW, Antonarakis SE et al (1985) Linkage map of the short arm of human chromosome 11: location of the genes for catalase, calcitonin, and insulin-like growth factor II. Proc Natl Acad Sci U S A 82:5064–5067
11. Nuesch E, Schmidt R (1980) Comparative pharmacokinetics of calitonins. In: Pecile A (ed) Calcitonin 1980. Proc Int Symp Milan; pp 352–364
12. Miacalcin® (calcitonin-salmon) nasal spray package insert (2014) Novartis Pharmaceuticals Corporation, East Hanover, NJ
13. Binkley N, Bolognese M, Sidorowicz-Bialynicka A et al (2012) A phase 3 trial of the efficacy and safety of oral recombinant calcitonin: the Oral Calcitonin in Postmenopausal Osteoporosis (ORACAL) trial. J Bone Miner Res 27:1821–1829
14. Qvist P, Christgau S, Pederesen BJ et al (2002) Circadian variation in the serum cncentration of C-terminal telopeptide of Type I collagen (Serum CTx): effects of gender, age, menopausal stautus, posture, daylight, serum cortisol, and fasting. Bone 31:57–61
15. NOF (2014) Clinician’s guide to prevention and treatment of osteoporosis. National Osteoporosis Foundation, Washington
16. U.S. Preventative Services Task Force (2011) Screening for osteoporosis: U.S. Preventative Services Task Force recommnedation statement. Ann Int Med 154:356–364
17. Black DM, Bauer DC, Schwartz AV et al (2012) Continuing bisphosphonate treatment for osteoporosis—for whom and for how long? N Engl J Med 366:2051–2053
18. Whitaker M, Guo J, Kehoe T et al (2012) Bisphosphonates for osteoporosis—where do we go from here? N Engl J Med 366:2048–2051
19. Ronckers CM, McCarron P, Ron E (2005) Thyroid cancer and multiple primary tumors in the SEER cancer registries. Int J Cancer 117:281–288
20. Food and Drug Administration (2013) Background document for meeting of Advisory Committee for reproductive health drugs and drug safety and risk management advisory committee
21. Krause D, Hernandez NAS, Vitagliano M et al (2012) One year use of oral recombinant salmon calcitonin is not associated with increased risk of cancer. J Bone Miner Res 27(suppl 1)
22. Wells G, Krause D, Chernoff J et al (2013) Does calcitonin-salmon cause cancer? Poster session presented at American Society of Bone and Mineral Research Annual Meeting, Oct 4–7, Baltimore MD